Efficacy and safety of tocilizumab in treatment of Takayasu arteritis: A systematic review of randomized controlled trials - PubMed (original) (raw)

Efficacy and safety of tocilizumab in treatment of Takayasu arteritis: A systematic review of randomized controlled trials

Ambrish Singh et al. Mod Rheumatol. 2021 Jan.

Abstract

Background: Takayasu arteritis (TAK) is a chronic immune vasculitis in which Interleukin-6 (IL-6) receptors play a key role in pathogenesis. Tocilizumab (TCZ), an IL-6 receptor antagonist with a favorable safety and efficacy profile, has been tried as an option for patients with TAK. This systematic review analyzed the evidence from randomized control trials (RCT) assessing the safety and efficacy of TCZ in patients with TAK.

Methods: MEDLINE, Embase, the Cochrane Library, and clinical trial registries were searched from inception to July 2018. We included RCT assessing the efficacy and safety of TCZ versus placebo/other comparators for the treatment of patients with TAK. The risk of bias (RoB) was assessed using Cochrane RoB tool.

Results: 2799 identified articles were screened as per abstract and title; 42 selected full-texts articles were assessed for the potential inclusion. One trial, reported in two publications, comparing subcutaneous TCZ (162 mg/week) versus matching placebo in 36 patients with TAK was included. The relapse-free rate at 24 weeks was 50.6% and 22.9% in TCZ and placebo arm, respectively. The hazard ratio (HR) for time to first relapse was statistically significant in the per-protocol population (HR 0.34 [95.41% CI, 0.11-1.00]; p = .0345), while non-significant in the intention-to-treat population (HR 0.41 [95.41% CI, 0.15-1.10]; p = .0596). The serious adverse events were higher in the placebo arm.

Conclusions: This systematic review finds the existing evidence from RCT on efficacy and safety profile of TCZ in TAK to be promising but limited. Additional evidence is required to draw a stronger conclusion.

Keywords: Takayasu arteritis; large vessel vasculitis; meta-analysis; systematic review; tocilizumab.

PubMed Disclaimer

Cited by

Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis.
Kang L, Liu Y, Luo Z, Zhou Y, Chen B, Yin G, Xie Q. Kang L, et al. Front Immunol. 2023 Feb 8;14:1084558. doi: 10.3389/fimmu.2023.1084558. eCollection 2023. Front Immunol. 2023. PMID: 36845158 Free PMC article.
Wind of Change in the Treatment of Childhood-Onset Takayasu Arteritis: a Systematic Review.
Sener S, Basaran O, Ozen S. Sener S, et al. Curr Rheumatol Rep. 2021 Jul 3;23(8):68. doi: 10.1007/s11926-021-01032-8. Curr Rheumatol Rep. 2021. PMID: 34218346 Review.
Renal AA amyloidosis leading to early diagnosis and treatment of takayasu arteritis: a case report and review of the literature.
Kos I, Stilgenbauer S, Bewarder M. Kos I, et al. Clin Res Cardiol. 2020 Nov;109(11):1438-1441. doi: 10.1007/s00392-020-01655-4. Epub 2020 Apr 28. Clin Res Cardiol. 2020. PMID: 32346768 Free PMC article. Review. No abstract available.
Physical Therapy Exercises for Sleep Disorders in a Rehabilitation Setting for Neurological Patients: A Systematic Review and Meta-Analysis.
Tramontano M, De Angelis S, Galeoto G, Cucinotta MC, Lisi D, Botta RM, D'ippolito M, Morone G, Buzzi MG. Tramontano M, et al. Brain Sci. 2021 Sep 5;11(9):1176. doi: 10.3390/brainsci11091176. Brain Sci. 2021. PMID: 34573197 Free PMC article. Review.
The Immunobiological Agents for Treatment of Antiglomerular Basement Membrane Disease.
Yamashita M, Takayasu M, Maruyama H, Hirayama K. Yamashita M, et al. Medicina (Kaunas). 2023 Nov 16;59(11):2014. doi: 10.3390/medicina59112014. Medicina (Kaunas). 2023. PMID: 38004064 Free PMC article. Review.

Efficacy and safety of tocilizumab in treatment of Takayasu arteritis: A systematic review of randomized controlled trials - PubMed (original) (raw)